{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:40:50Z","timestamp":1786621250232,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"publisher","award":["SVV 260663"],"award-info":[{"award-number":["SVV 260663"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministry of Education Youth and Sports of the Czech Republic","doi-asserted-by":"publisher","award":["LM2023041"],"award-info":[{"award-number":["LM2023041"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["NU23-08-00214"],"award-info":[{"award-number":["NU23-08-00214"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.nucmedbio.2026.109637","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:15:15Z","timestamp":1779725715000},"page":"109637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Biodistribution of 161Tb- or 177Lu-labeled immunoconjugate in comparison with its potential metallic radioactive degradation products and contaminants"],"prefix":"10.1016","volume":"158-159","author":[{"given":"Pavel","family":"B\u00e1rta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikta","family":"Mehdizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Sk\u00e1lov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Jansk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Vlk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Kucha\u0159ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1n","family":"Kozempel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franti\u0161ek","family":"Trejtnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2026.109637_bb0005","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/14712598.2017.1322577","article-title":"Radioimmunoconjugates for treating cancer: recent advances and current opportunities","volume":"17","author":"Bourgeois","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0010","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3390\/cancers14061454","article-title":"Radiolabeled antibodies for cancer imaging and therapy","volume":"14","author":"Parakh","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0015","first-page":"443","article-title":"A review of advances in the last decade on targeted cancer therapy using 177Lu: focusing on 177Lu produced by the direct neutron activation route","volume":"11","author":"Chakravarty","year":"2021","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0020","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1021\/cr500171e","article-title":"Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications","volume":"115","author":"Banerjee","year":"2015","journal-title":"Chem Rev"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40658-020-00301-2","article-title":"Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases","volume":"7","author":"Alcocer-\u00c1vila","year":"2020","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0030","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.nucmedbio.2011.02.007","article-title":"The low-energy \u03b2- and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy","volume":"38","author":"Lehenberger","year":"2011","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0035","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1007\/s00259-023-06316-y","article-title":"Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics","volume":"50","author":"M\u00fcller","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0040","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.7150\/thno.92775","article-title":"Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside","volume":"14","author":"Van Laere","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0045","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.addr.2008.04.006","article-title":"Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides","volume":"60","author":"Liu","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0050","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.3390\/molecules27103062","article-title":"The chemical scaffold of theranostic radiopharmaceuticals: radionuclide, bifunctional chelator, and pharmacokinetics modifying linker","volume":"27","author":"Holik","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-0716-3499-8_8","article-title":"Methods for the production of radiolabeled bioagents for ImmunoPET","volume":"2729","author":"Arroyo","year":"2024","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0060","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.7150\/thno.57177","article-title":"Perspectives on metals-based radioimmunotherapy (RIT): novin forward","volume":"11","author":"White","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0065","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jlcr.3707","article-title":"Preparation of 177Lu-labeled Nimotuzumab for radioimmunotherapy of EGFR-positive cancers: comparison of DOTA and CHX-A\u2033-DTPA as bifunctional chelators","volume":"62","author":"Pandey","year":"2019","journal-title":"J Labelled Comp Radiopharm"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0070","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.nucmedbio.2021.03.007","article-title":"AAZTA5-squaramide ester competing with DOTA-, DTPA- and CHX-A\u2033-DTPA-analogues: promising tool for 177Lu-labeling of monoclonal antibodies under mild conditions","volume":"96-97","author":"Klasen","year":"2021","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0075","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1007\/s11095-014-1584-z","article-title":"Preclinical pharmacokinetic considerations for the development of antibody drug conjugates","volume":"32","author":"Kamath","year":"2015","journal-title":"Pharm Res"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0080","doi-asserted-by":"crossref","first-page":"769","DOI":"10.4155\/tde.11.41","article-title":"Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology","volume":"2","author":"Prabhu","year":"2011","journal-title":"Ther Deliv"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0085","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1208\/s12248-025-01115-9","article-title":"Recent advances in bioanalytical methods for quantification and pharmacokinetic analyses of antibody-drug conjugates","volume":"27","author":"Khan","year":"2025","journal-title":"AAPS J"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0090","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00259-013-2563-z","article-title":"Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate","volume":"41","author":"M\u00fcller","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0095","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","article-title":"Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms","volume":"49","author":"Borgna","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0100","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00259-014-2798-3","article-title":"Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model","volume":"41","author":"Gr\u00fcnberg","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2025.108998","article-title":"Terbium-161 in nuclear medicine: Preclinical and clinical progress in comparison with lutetium-177","volume":"144-145","author":"Trejtnar","year":"2025","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41181-019-0063-6","article-title":"Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy","volume":"4","author":"Gracheva","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0115","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00306741","article-title":"Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats","volume":"17","author":"L\u00e1zn\u00ed\u010dkov\u00e1","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0120","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bmcl.2014.12.016","article-title":"A comparative study of trans-and cis-isomers of a bone-seeking agent, DO2A2P","volume":"25","author":"Hao","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0125","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1039\/c2dt32373g","article-title":"In vitro studies of lanthanide complexes for the treatment of osteoporosis","volume":"42","author":"Mawani","year":"2013","journal-title":"Dalton Trans"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0130","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00228-024-03734-1","article-title":"Efficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis","volume":"80","author":"Ren","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1021\/acs.bioconjchem.0c00015","article-title":"Bioconjugates of chelators with peptides and proteins in nuclear medicine: historical importance, current innovations, and future challenges","volume":"31","author":"Jackson","year":"2020","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/ijms18010057","article-title":"Immuno-PET for clinical theranostic approaches","volume":"18","author":"Bailly","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0145","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.nucmedbio.2007.04.001","article-title":"Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view","volume":"34","author":"Boswell","year":"2007","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0150","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2967\/jnumed.125.270508","article-title":"Radiolabeling of CHX-A\u2033-DTPA-antibody conjugates with [89Zr]ZrCl4","volume":"67","author":"Lyashchenko","year":"2026","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0155","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.nucmedbio.2016.06.004","article-title":"A comparative evaluation of the chelators H4octapa and CHX-A\u2033-DTPA with the therapeutic radiometal (90)Y","volume":"43","author":"Price","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0160","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s11307-025-02013-4","article-title":"Targeted radionuclide therapy using a Lutetium-177 labeled human anti-CD133 antibody","volume":"27","author":"Wyszatko","year":"2025","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0165","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jlcr.3909","article-title":"Preclinical evaluation of anti-VEGFR2 monoclonal antibody ramucirumab labelled with zirconium-89 for tumour imaging","volume":"64","author":"Novy","year":"2021","journal-title":"J Labelled Comp Radiopharm"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0170","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00259-024-07018-9","article-title":"Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form","volume":"52","author":"Wallimann","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0175","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0730-725X(92)90016-S","article-title":"Dissociation of gadolinium chelates in mice: relationship to chemical characteristics","volume":"10","author":"Wedeking","year":"1992","journal-title":"Magn Reason Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0180","first-page":"705","article-title":"Development of (177)Lu-phytate complex for radiosynovectomy","volume":"16","author":"Yousefnia","year":"2013","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0185","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10517-006-0373-z","article-title":"Intralysosomal accumulation of gadolinium and lysosomal damage during selective depression of liver macrophages in vivo","volume":"142","author":"Korolenko","year":"2006","journal-title":"Bull Exp Biol Med"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0001-2998(76)80032-3","article-title":"Bone scanning: radionuclidic reaction mechanisms","volume":"6","author":"Jones","year":"1976","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0195","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0300-9084(82)80290-3","article-title":"M\u00f6ssbauer spectroscopy and perturbed angular correlation studies of the rare-and alkaline-earth bone uptake","volume":"63","author":"Rimbert","year":"1981","journal-title":"Biochimie"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0200","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1109\/TNB.2018.2830812","article-title":"Highly stable 177Lu-organic framework as a potential agent for treatment of metastatic bone","volume":"17","author":"Salek","year":"2018","journal-title":"IEEE Trans Nanobioscience"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.109.002014","article-title":"Xenobiotic, bile acid, and cholesterol transporters: function and regulation","volume":"62","author":"Klaassen","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.nucmedbio.2026.109637_bb0210","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/jlcr.3352","article-title":"The in vivo disposition and in vitro transmembrane transport of two model radiometabolites of DOTA-conjugated receptor-specific peptides labelled with 177Lu","volume":"58","author":"Volkov\u00e1","year":"2015","journal-title":"J Labelled Comp Radiopharm"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:26:13Z","timestamp":1786620373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805126000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":42,"alternative-id":["S0969805126000363"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109637","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biodistribution of 161Tb- or 177Lu-labeled immunoconjugate in comparison with its potential metallic radioactive degradation products and contaminants","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109637"}}